|
Stem Cells - The Hype and the Hope 2010-2025
|
|||||||||||
| Zahlen und Fakten zur Studie: |
This report gives you the following benefits in particular: 201 seiten | |||||||||||
| Inhalt der Studie: |
In 2010, the stem cells market stands on the brink of technological and commercial breakthroughs, our new study explains. For the first time, pharmaceutical companies are beginning to invest significa.....
In 2010, the stem cells market stands on the brink of technological and commercial breakthroughs, our new study explains. For the first time, pharmaceutical companies are beginning to invest significantly in the drive to create new treatments based on embryonic and adult stem cells. As this research gathers pace, with clinical trials commencing, the potential of stem cells in medicine may relatively soon be fulfilled. Results in animals indicate that stem cells may provide treatment options for a range of disorders and restorative applications including multiple sclerosis, diabetes, Parkinson's disease, Alzheimer's disease, spinal cord injury, blindness, immune system disorders and cardiovascular disease. Stem Cells - The Hype and the Hope 2010-2025 provides an analytical overview of this burgeoning sector, with technologies and commercial potential discussed and forecasted. The sector will gather momentum as stem cell therapies start to emerge from the R&D pipeline from this decade onwards. In this report we assess the disease areas in which stem cell therapies are most likely to emerge, with overviews of the commercial and academic research being carried out in subsectors of healthcare. We analyse the short-, medium- and long-term prospects for stem cell breakthroughs in disease areas, providing the information that you require. Our new report also provides a review of leading companies that currently seek to harness stem cell technologies. The research areas of each company are profiled, with discussion of the approaches being used. Some organisations are developing scalable therapies with allogeneic stem cells, while others investigate personalised treatments using autologous stem cells. Other organisations pursue research in the embryonic stem cells field, which has opened up in the US, with fewer obstacles and greater funding opportunities available since 2009. Some companies already generate revenues from stem cells by carving out market niches in stem cell supply, such as stem cells for drug development and toxicity assays, or services such as stem cell banking in umbilical cord blood. We analyse the main divisions of the market, providing revenue forecasts for 2010 to 2025. Comprehensive analysis of the global stem cells market Stem Cells - The Hype and the Hope 2010-2025 examines that sector through a comprehensive review of information sources. We use primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are comprehensive tables and figures, as well as four interviews with experts. The result is a detailed market- and industry-centred study, with analyses and informed opinion to benefit your work. Why you should buy Stem Cells - The Hype and the Hope 2010-2025 Our research shows that stem cells hold the potential to change medicine in decades to come, with benefits to healthcare stakeholders starting to appear during our forecast period, 2010 to 2025. We separate the real potential from the wishful thinking in this complex field. Report Highlights Companies Listed Aastrom Biosciences Advanced Cell Technology Aldagen Alliance Technology Ventures Amorcyte AmStem International Angioblast Systems Anthony Nolan Trust Assisted Human Reproductions Agency AstraZeneca Athersys Australian Stem Cell Centre Axiogenesis AXM Pharma Biogenea-CellGenea Bioheart Bio-Matrix Scientific Group Biomimetic Therapeutics BioTime Boston Scientific Corporation BrainStorm Cell Therapeutics Bresagen Burnham Institute for Medical Research, University of California Calibochem Canadian Institute of Health Cardiogenesis Corp. Casey Eye Institute Cellartis CellCure Neurosciences CellCyte Genetics Corporation Cellerix Cellgene Corporation Cellular Dynamics International Cellular Engineering Technologies Celprogen CEL-SCI Corporation Centocor Ortho Biotech CHA Biotech Children's Hospital of Orange County Children's Hospital & Research Center in Oakland, California Cleveland Clinic Clinical Research Facility for Stem Cells and Regenerative Medicine, Hyderabad Columbia University Comment on Reproductive Ethics (CORE) CorCell Cord Blood America Cord Blood Registry Cordon Vital (CBR) Cryo-Cell International CyThera Cytori Therapeutics Diostech Embryome Sciences ES Cell International (Singapore) European Medicines Agency (EMEA) European Union Group on Ethics (EGE), The EyeCyte Fate Therapeutics Fibrocell Fisher Scientific Foundation for Taxpayer and Consumer Rights, The Gamida Cell Garnet BioTherapeutics GE Healthcare Genzyme Geron Corporation Gladstone Institute of Cardiovascular Disease GlaxoSmithKline Hadasit Bio-Holdings Hadassah University Hospital Harvard Stem Cell Institute Harvard University HepaLife Technologies Histostem Human Fertilisation and Embryology Authority (HFEA, UK) HyClone Indiana University International Society of Stem Cell Research International Stem Cell Corporation iPS Cells Isolagen Israeli Health Ministry Johns Hopkins University Johnson & Johnson Korea Stem Cell Bank Co. LifebankUSA LifeCell India Lifeline Cell Technology LifeStem London Breast Institute, Princess Grace Hospital London Development Agency London Regenerative Medicine Network (LRMN) Maxim Biotech Mayo Clinic MedCell Biosciences Medical College of Georgia Medistem Merck & Co. Merck KGaA Merck Serono Mesoblast Multicell Technologies Muslim World League Mytogen NASA National Institutes of Health (NIH, US) National Health Service (NHS, UK) National Tissue Engineering Center (Shanghai) Neostem Neuralstem Neuronyx Northwestern University Novartis Novartis Institutes for BioMedical Research (NIBR) Novo Nordisk Novocell NuVasive Opexa Therapeutics Organogenesis Orthofix Osiris Therapeutics OST Developpement Osteotech Patient Patent Foundation Pfizer Pluristem Therapeutics Primogenix ProLife Alliance, The Proteus Venture Partners Purdue University Indianapolis Reeve-Irvine Research Centre Regenetech RegenRx Reliance Life Sciences, India ReNeuron Reproductive Genetics Institute (Chicago) RNL Bio Roche Royal Veterinary College, The Royan Institute (Tehran) RTI Biologics Rutgers University Safeguard Scientifics SCP Vitalife Partners Singapore Stem Cell Consortium Stanford University Stem Cell & Regenerative Medicine International Stem Cell Authority Stem Cell Innovations (SCI) Stem Cell Products Stem Cell Sciences Stem Cell Therapeutics Corp. Stem Cell Therapy International Stem Cells Research Forum of India (SCRFI) StemCell Technologies StemCells StemCells Stemgent StemLifeLine Stemride International Limited (SIL) SUNY Upstate Medical University Suzhou Erye Pharmaceuticals TCA Cellular Therapy Tengion Texas A&M University The Food and Drug Administration (FDA) Thermo Electron Thermo Fisher Scientific Thermogenesis Corp. Transition Holdings U.S. Army Institute of Surgical Research (USAISR) U.S. Department of Defense United States of America Patent and Trademark Office University College London University of Amsterdam University of California at Irvine University of California at San Diego University of Edinburgh University of Florida University of Helsinki University of Kyoto University of Miami University of Michigan University of Oklahoma University of Pittsburgh University of South Florida University of Texas, Medical Branch at Galveston University of Virginia University of Wisconsin UT Southwestern Medical Center Vantus Veritas Corporation VetCell Bioscience Limited VetStem ViaCord Vitro Biopharma Vitro Diagnostics Voss Laboratories Wake Forest University Wisconsin Alumni Research Foundation (WARF) Wolfson Centre for Age-Related Diseases (part of King's College, University of London) [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Stem Cells Market Review 1.2 Crucial Aspects of the Stem Cells Market 1.3 Aims, Scope and Format of this Report 1.3.1 Speculative Aspects of Assessing the Stem Cell Field 1.3.2 Chapter Outline 1.4 Research and Analysis Methods 2. Stem Cells: An Introduction 2.1 Stem Cells in 2010: Overview of the Sector 2.2 The Basics: What Are Stem Cells? 2.3 Stem Cell Potency 2.3.1 Totipotency 2.3.2 Pluripotency 2.3.3 Multipotency 2.3.4 Oligopotency 2.3.5 Unipotency 2.3.6 Stem Cells and Progenitor Cells 2.4 Embryonic Stem Cells 2.4.1 Abortion Debates, IVF, and Embryonic Stem Cells 2.4.2 Harvesting Human Eggs 2.5 Adult Stem Cells 2.5.1 Sources of Adult Stem Cells 3. Issues Affecting the Stem Cells Market, 2010 3.1 Strengths 3.1.1 Stem Cells Have Great Therapeutic Potential 3.1.2 Stem Cells Could Revolutionise Our Understanding of Disease 3.1.3 Animal Models Yield Impressive Results 3.1.4 Stem Cells Already Have Some Therapeutic Applications 3.1.5 The Stem Cells Field Has Strength in Numbers 3.1.6 Discoveries Are Being Made at a Rapid Rate 3.1.7 Adult Stem Cells: Fewer Ethical Controversies 3.1.8 Many Governments Support Adult Stem Cell Research 3.1.9 Stem Cells Have Proven Uses and Marketability Beyond Their Directly Therapeutic Applications 3.1.10 The Market Offers Multiple Business Models 3.2 Weaknesses 3.2.1 Therapies Take Time 3.2.2 Stem Cells and Cancer 3.2.3 The Safety-First Approach 3.2.4 Embryonic Stem Cell Supply Problems 3.2.5 Business Model Problems with Autologous Therapies 3.2.6 Donor Rejection Risk with Allogeneic Therapies 3.2.7 The Research Field is Fragmented 3.2.8 The IP Minefield 3.2.9 Government Money is Required: Little Venture Capital - Yet 3.2.10 Problems Adapting Pharmaceutical Business Model to Stem Cells 3.3 Opportunities 3.3.1 Therapies: Almost Anything Could Happen 3.3.2 The Attractions of the Stem Cells Market 3.3.3 Asia Harnesses Stem Cells Opportunities 3.3.3.1 China: Favourable Regulations 3.3.3.2 Japan: Liberal hESC Policy 3.3.3.3 Singapore: Advanced and Prominent 3.3.3.4 South Korea: Stem Cells a National Priority 3.3.3.5 India: First Official Research Hub Opened in 2009 3.3.3.6 Israel: at The Forefront 3.3.3.7 Gulf Countries: Funding Stem Cell Research 3.3.4 Adipose Tissue Opportunities for IPSCs 3.3.5 Beyond Pluripotency 3.3.6 Pharmaceutical Laws Do Not Apply to Stem Cell Therapies 3.3.7 Unique Disease Modelling Possibilities With IPS Cells 3.3.8 High Net-Worth Individuals: A Possible Source of Stem Cell Capital 3.3.9 The Opportunity to Get There First 3.3.10 Public Perception of Stem Cells Represents an Opportunity 3.4 Threats 3.4.1 The Risks of the Regulatory Environment 3.4.1.1 North America 3.4.1.2 Europe 3.4.2 Lack of Embryonic Stem Cell Diversity in US Research 3.4.3 Not Everyone Can Succeed in The Stem Cells Market 3.4.4 The Risk of Public Disenchantment 3.4.5 High-Profile Failures in Stem Cell Supply 3.4.6 High-Profile Failures in Stem Cell Therapies 3.4.7 Scare Stories and Perception Problems 3.4.8 Economic Instability 3.4.9 Market Fluidity is a Threat 3.4.10 Are Stem Cells Too Revolutionary for the Existing Pharmaceuticals Model? 4. The Stem Cell Market in 2010 4.1 The Stem Cell Market Was Worth Around $2.8bn in 2009 4.1.1 Where The Money is: Divisions of the Stem Cells Market in 2010 4.2 Stem Cell Therapies 4.2.1 Existing Stem Cell Therapies Market 4.2.2 Diseases Treated With Adult Stem Cells In 2010 4.2.3 Bone Marrow Transplants 4.2.3.1 The Transplant Process 4.2.3.2 The Results 4.2.4. Peripheral Blood Stem Cell Transplants 4.2.5 Cord Blood Stem Cell Transplants 4.2.6 Allogeneic Transplants vs. Autologous Transplants 4.2.6.1 Allogeneic Transplants are Better for Killing Cancer 4.2.6.2 The Problem with Allogenic Transplants: Graft-versus-Host Disease and Host-versus-Graft Disease 4.2.6.3 Saviour-Siblings: Stem Cells from a Sibling, Created or Chosen to be a Saviour 4.2.6.4 UK Cases and Rules on Saviour Siblings 4.2.7 Other Surgery Involving Stem Cells 4.2.8 Osteocel and other Bone Regeneration Products 4.2.9 Stem Cells and Regenerative Medicine 4.2.9.1 Organogenesis 4.2.9.2 Stem Cell Therapeutics 4.2.9.3 CEL-SCI Corporation 4.2.9.4 Osteotech 4.2.9.5 RegeneRx 4.2.9.6 RTI Biologics 4.2.9.7 Biomimetic Therapeutics 4.2.9.8 Fibrocell 4.2.10 Stem Cell Cosmetics 4.2.10.1 Breast Enhancement 4.2.10.2 Topical "Stem Cell" Preparations 4.2.11 Unregulated Stem Cells Therapies 4.3 Stem Cell Services 4.3.1 The Market for Stem Cell Services 4.3.2 Some of the Companies in the Stem Cell Services Market 4.3.2.1 Cellular Dynamics International: Cardiomyocyte Technology 4.3.2.2 Fate Therapeutics: Stem Cells for Drug Discovery 4.3.2.3 International Stem Cell Corporation: Parthenogenetic Cell Line Bank 4.3.2.4 Axiogenesis: Research Tools 4.3.2.5 Vitro Biopharma: Longer-Lasting Cell Line Expansion Periods 4.3.2.6 CellCyte Genetics: Expansion Bioreactor 4.3.2.7 MultiCell Technologies: Liver Stem Cell Lines 4.3.2.8 Stemgent: Stem Cell Scientists 4.3.2.9 Regenetech: Stem Cell Expansion Leaders 4.3.2.10 Pfizer/Novocell: Pancreatic Cell Lines 4.3.2.11 Biotime: 200+ Patent Portfolio 4.3.2.12 StemLifeLine: Embryonic Stem Cells Without Embryo Destruction? 4.3.2.13 Stem Cell Innovations (SCI): PluriCells Platform 4.3.2.14 HyClone/Thermo Fisher Scientific: 40 Years of Cell Culture Products 4.3.2.15 Merck/Calibochem/Stem Cell Sciences: Drug Screening Assays 4.3.2.16 Stemride International Limited (SIL) and Reproductive Genetics Institute, Chicago: Normal and Abnormal Cell Lines 4.3.2.17 ES Cell International, Singapore: Hoping for the First Marketed Product Including Embryonic Stem Cells 4.3.2.18 StemCell Technologies: ES Cells and Cell Culture Supplies 4.3.2.19 Bio-Matrix Scientific Group: Cryopreservation 4.4 Blood Banking 4.4.1 Biological Insurance: Private Blood Banking 4.4.2 Umbilical Cord Banking: The Controversies 4.4.2.1 US Oversight of Cord Blood Stem Cells 4.4.3 The Market for Blood Banking 4.4.4 Companies in the Field 4.4.4.1 Cord Blood America: Looking Towards the Chinese Market 4.4.4.2 ViaCord: 145,000 Blood Units in Storage 4.4.4.3 Cryo-Cell International: The First Cord Blood Bank 4.4.4.4 Stem Cell Authority: Exclusive Stem Cells 4.4.4.5 LifebankUSA: Placenta-Cord Banking 5. The New Stem Cell Therapies I: Companies and Business Models 5.1 In Search of a Stem Cells Business Model 5.1.1 Embryonic or Adult? 5.2 Stem Cell Companies in the Media Spotlight 5.2.1 Towards the First Human Trials of Embryonic Stem Cells 5.2.2 Adult Stem Cells: Collaborations with Pharmaceutical Giants 5.3 Embryonic Stem Cells 5.3.1 Geron: First Embryonic Stem Cell Trial 5.3.1.1 Geron and GE Healthcare 5.3.2 Advanced Cell Technology (ACT) 5.3.2.1 Competition for ACT in Macular Degeneration Treatment 5.3.2.2 ACT Deals with Other Companies 5.3.3 Novocell: Looking to Follow Geron and ACT in Embryonic Stem Cells Trials 5.3.3.1 Novocell's Collaborations with Pharmaceutical Leaders 5.3.4 CellCure Neurosciences 5.3.5 Royan Institute (Tehran) 5.3.6 Reliance Life Sciences, India 5.4 Adult Stem Cell Therapies: Allogeneic 5.4.1 Osiris: First to Market with Stem Cells 5.4.1.1 Osiris and NuVasive 5.4.1.2 Osiris and Genzyme 5.4.1.3 Prochymal: Great Promise but How is Work Shaping Up? 5.4.1.4 What Next for Prochymal? 5.4.2 Athersys 5.4.2.1 Multistem: an Off-The-Shelf Allogeneic Stem Cell Therapy 5.4.3 StemCells 5.4.4 MediStem (MediStem Laboratories, Inc.) 5.4.5 ReNeuron 5.4.6 Pluristem Therapeutics 5.4.7 Amstem International (Stem Cell Therapy International/Histostem) 5.4.8 Neuralstem 5.4.9 Garnet BioTherapeutics/Neuronyx 5.4.10 HepaLife Technologies 5.5 Adult Stem Cells: Autologous Therapies 5.5.1 Opexa Therapeutics 5.5.1.1 Tovaxin 5.5.2 Cellerix: Ontaril has EMEA Orphan Drug Status 5.5.3 Aastrom Biosciences 5.5.4 Bioheart 5.5.5 Cardiogenesis: Autologous Medical Devices 5.5.6 BrainStorm Cell Therapeutics 5.5.7 Cytori Therapeutics 5.5.8 TCA Cellular Therapy 5.5.9 Autologous Cell Storage 5.5.9.1 LifeStem: Two Sources of Stem Cells Preserved 5.5.9.2 Neostem: Success with Bone Marrow Stem Cell Storage 5.5.9.3 Thermogenesis: Autologous Cryopreservation 5.5.9.4 Biogenea-CellGenea: Leading Stem Cell Research Facility in the EU 6. The New Stem Cell Therapies II: Indications 6.1 The Growth of the Stem Cells Market to 2025 6.2 Near-Term Indications 6.2.1 Cancer 6.2.1.1 Cancer Stem Cells 6.2.2 Immune Disorders 6.2.3 Eye Diseases 6.2.4 Orthopaedics 6.2.5 Diabetes 6.2.6 Other Likely Near-Term Indications 6.2.6.1 Acute Radiation Syndrome 6.3 Cardiovascular Diseases 6.4 Brain and Central Nervous System Diseases 6.4.1 Amyotrophic Lateral Sclerosis (ALS, Lou Gherig's Disease) 6.4.2 Multiple Sclerosis 6.4.3 Alzheimer's Disease 6.4.4 Cerebral Palsy 6.4.5 Pelizaeus-Merzbacher Disease (PMD) 6.4.6 Parkinson's Disease 6.4.7 Spinal Cord Injury 6.5 Growing Organs 6.6 Other Possible Indications for Stem Cells 6.6.1 Autism 6.6.2 HIV and Other Viral Diseases 6.6.3 Fertility Treatment 7. Interviews with Experts 7.1 Dr Johan Luthman, Merck Serono 7.1.1 Difficulties of Translational Medicine 7.1.2 Differences Between Technology and Media Perceptions 7.1.3 Confusion in the Media 7.1.4 Stem Cells and Neurologic Disorders 7.1.4.1 Which Neurological Disorders will be Treated First? 7.1.4.2 Multiple Sclerosis 7.1.5 Why Stem Cell Results Take a Long Time 7.1.6 When Stem Cell Therapies Will Reach the Market 7.1.7 The Distinction between Regenerative Medicine and Stem Cell Therapies 7.2 Dr Stephen Minger, Wolfson Centre for Age-Related Diseases, King's College London 7.2.1 On Whether Adult or Embryonic Stem Cells Should Receive More Funding/Support 7.2.2 Cord Blood and Embryonic Stem Cells 7.2.3 The Need for More Immunological Assays 7.2.4 How Long Until there are Human Stem Cell Therapies? 7.2.5 Cord Blood as a Source of Stem Cells 7.2.6 Private Cord Blood Banking 7.2.7 Therapeutic Cloning 7.2.7.1 Therapeutic Cloning and Tissue Type Cell Lines 7.2.8 Promising and Unusual Immunological Properties of Embryonic Stem Cells 7.2.9 Mesenchymal Stem Cells and Inflammation 7.2.10 On the Use of Foreskin Fibroblasts 7.3 Gregory Bonfiglio, Proteus Venture Partners 7.3.1 On the Terms "Stem Cell Therapy" and "Regenerative Medicine" 7.3.2 On "Near Term" Applications 7.3.3 Value-Creation Curve for Venture Capital in Stem Cells 7.3.4 On There Being No Known Limits on Stem Cell Possibilities 7.3.5 On Stem Cells in 25 Years 7.3.6 Funding as a Primary Limitation? 7.3.7 Stem Cells in Multiple Sclerosis and Diabetes Type 1 7.3.8 Cord Blood 7.3.9 Extracellular Matrixes 7.3.10 Disease-Specific Cell Lines 7.3.11 Adult vs. Embryonic Stem Cells 7.3.12 Capital for Stem Cell and Regenerative Medicine Research 7.4 Josephine Quintavalle, Founder of Comment on Reproductive Ethics (CORE) 7.4.1 Embryonic Stem Cells and Dehumanisation 7.4.2 HFEA Regulation on Embryo Destruction 7.4.3 Economics and Scientific Effectiveness 7.4.4 Cord Blood 7.4.5 Adult Stem Cell Therapies and the Economics of Therapy 7.4.6 Public, Private and Private/Public Cord Blood Banks 7.4.7 International Studies and International Communication 8. Conclusions 8.1 The Stem Cell Market in 2010 is Small, But Will Grow Rapidly 8.2 The Stem Cell Therapies Market is on The Brink of Significant Growth 8.3 Induced Pluripotent Adult Stem Cells May Revolutionise the Market 8.4 The Sector Has Marked Uncertainties, But Many Opportunities [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Potency and Source of Stem Cells Table 2.2 Germ Layers and Their Associated Types of Cells and Organs Table 3.1 SWOT Analysis of the Stem Cells Sector, 2010 Table 4.1 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025 Table 4.2 Some Diseases That Have Been Treated With Adult Stem Cells, 2010 Table 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015 Table 4.4 Some Companies in the Regenerative Medicine Sector, 2010 Table 4.5 Stem Cell Services: Sales Forecast ($m), 2010-2025 Table 4.6 Some Companies in the Stem Cell Services Market, 2010 Table 4.7 Cord Blood Banking: Sales Forecast ($m), 2010-2025 Table 4.8 Some Companies in the Cord Blood Banking Market, 2010 Table 5.1 Some Companies in the Embryonic Stem Cell Therapies Sector, 2010 Table 5.2 Some Companies in the Allogeneic Adult Stem Cell Therapies Sector, 2010 Table 5.3 Some Companies in the Autologous Adult Stem Cell Therapies Sector, 2010 Table 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025 Table 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025 Table 8.1 Total Stem Cells Market: Sales Forecast by Sector ($m), 2010-2025 Figure 4.1 Sectors of the Stem Cells Market: Sales ($bn), 2009 Figure 4.2 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025 Figure 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015 Figure 4.4 Stem Cell Services: Sales Forecast ($m), 2010-2025 Figure 4.5 Cord Blood Banking: Sales Forecast ($m), 2010-2025 Figure 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025 Figure 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
